MRC trial of α2b-interferon maintenance therapy in first plateau phase of multiple myeloma

British Journal of Haematology

Volumn 101, Issue 1, 1998, Pages 195-202

  Drayson, Mark T ^a   Chapman, Catherine E ^a   Dunn, Janet A ^a   Olujohungbe, Ade B ^a   Maclennan, Ian C M ^a,b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

2b interferon; Maintenance therapy; Multiple myeloma; Plateau phase; Randomized trial

Indexed keywords

BETA 2 MICROGLOBULIN; CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PARAPROTEIN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DISEASE COURSE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; DISEASE FREE SURVIVAL; MIDDLE AGED; RECURRENT DISEASE; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0032042194     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00648.x     Document Type: Article

References (31)

1. Abrahamson, G.M., Bird, J.M., Newland, A.C., Gaminara, E., Giles, C., Joyner, M., Kelsey, S.M., Lewis, D., McCarthy, D.M., Roques, A.W., Tew, C.J., Treacy, M., Van De Pette, J. & Samson, D. (1996) A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 94, 669-664.
2. Bergsagel, D.E., Vonwussow, P., Alexanian, R., Avvisati, G., Bataille, R., Barlogie, B., Borden, E., Caligariscappio, F., Deichen, H., Durie, B.C.M., Giles, F., Huhn, D., Klein, B., Kyle, R.A., Ludwig., H., Mellstedt, H., Peest, D., Salmon, S.E. & Westin, J. (1990) Interferons in the treatment of multiple myeloma. Journal of Clinical Oncology, 8, 1444-1445.
3. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353-1356.
4. Bladé, J., San Miguel, J.F., Escudero, M., Fontanillas, J., Besalduch, J., Gardella, S., Arias, J., Garcia-Conde, J., Martí, J.M., Estaphe, J. & Montserrat, E. (1997) Maintenance treatment with Interferon in multiple myeloma: the Spanish experience. In: Proceedings of the VI International Workshop on Multiple Myeloma (ed. by K. C. Anderson). Harvard University Press, Boston.
5. Browman, G.P., Bergsagel, D., Sicheri, D., O'Reilly, S., Wilson, K.S., Rubin, S., Belch, A., Shustik, C., Barr, R., Walker, I., James, K., Zee, B. & Johnston, D. (1995) Randomized trial of Interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 13, 2354-2360.
6. Cooper, E.H., Forbes, M.A., Crockson, R.A. MacLennan, I.C.M. (1984) Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. Journal of Clinical Pathology, 37, 852-858.
7. Cooper, M.R., Dear, K., McIntyre, O.R., Ozer, H., Ellerton, J., Canellos, G., Bernhardt, B., Duggan, D., Faragher, D. & Schiffer, C. (1993) A randomized clinical trial comparing melphalan/prednisone with or without Interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukaemia Group B study. Journal of Clinical Oncology, 11, 155-160.
8. 2-microglobulin compared with other presentation features in myelomatosis. British Journal of Cancer, 52, 1-6.
9. Dixon, W. Brown, M. & Engleman, L. (1985) BMDP Statistical Software Manual, 5th edn. University of California Press. Berkeley.
10. Joshua, D.E., Penny, R., Matthews, J.P., Laidlaw, C.R., Gibson, J., Bradstock, K., Wolf, M. & Goldstein, D., for the Australian Leukaemia Study Group (1997) Australian leukaemia study group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. British Journal of Haematology, 97, 38-45.
11. Jourdan, M., Zhang, X.G., Portier, M., Boiron, J.M., Bataille, R. & Klein, B. (1991) IFN-alpha induces autocrine production of IL-6 in myeloma cell-lines. Journal of Immunology, 147, 4402-4407.
12. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statisticians Association, 53, 457-467.
13. Ludwig, H., Cohen, A.M., Polliack, A., Huber, H., Nachbaur, D., Senn, H.-J., Morant, R., Eckhardt, S., Gunczler, P., Seewann, H.L., Schuller, J., Rhyner, K., Cavalli, F. & Fritz, E. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology, 6, 467-476.
14. Ludwig, H., Fritz, E., Neuda, J. & Durie, B.G. (1997) Patient preferences for interferon alfa in multiple myeloma. Journal of Clinical Oncology, 15, 1672-1679.
15. MacLennan, I.C.M., Chapman, C., Dunn, J. & Kelly, K., for the Medical Research Council Working Party for Leukaemia in Adults (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 339, 200-206.
16. MacLennan, I.C.M., Drayson, M. & Dunn, J. (1994) Current issues in cancer: multiple myeloma. British Medical Journal, 308, 1033-1036.
17. Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V.M., Marmont, F., Petrucci, M.T., Tribalto, M., Vegna, M.L., Dammacco, F. & Pileri, A. (1990) Maintenance treatment with recombinant Interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine, 20, 1430-1434.
18. McElwain, T.J. & Powles, R.L. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, ii, 822-824.
19. Mellstedt, H., Ahre, A., Bjorkholm, M., Holm, G., Johansson, B. & Strander, H. (1979) Interferon therapy in myelomatosis. Lancet, i, 245-247.
20. Osterborg, A., Bjorkholm, M. Bjoreman, M., Brenning, G., Carlson, K., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, H., Hast, R., Johansson, B., Juliusson, G., Jarnmark, M., Kimby, E. & Lerner, R., Linder, O., Merk, K., Nilsson, R., Ohrling, M., Paul, C., Simonsson, B., Smedmyr, B., Svedmyr, E., Stalfelt, A.M., Strander, H., Uden, A.M., Osby, E. & Mellstedt, H. (1995) Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood, 15, 1428-1434.
21. Peest, D., Deicher, H., Coldewey, R., Leo, R., Bartl, R., Bartels, H., Braun, H.J., Fett, W., Fischer, J.T., Gobel, B., Harms, P., Henke, R., Hoffmann, L., Kreuser, E.D., Maier, W.D., Meier, C.R., Oertel, J., Petit, M., Planker, M., Platzeck, C., Respondek, M., Schaffer, E., Schumacher, K., Stennes, M., Stenzinger, W., Tirier, C., Wagner, H., Weh, H.J., Vonwussow, P. & Wysk, J. (1995) A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group, European Journal of Cancer, 31, 146-151.
22. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1997) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and example. British Journal of Cancer, 35, 1-39.
23. Powles, R., Raje, N., Cunningham, D., Malpas, J., Milna, S., Horton, C., Mehta, J., Singhal, S., Viner, C. & Treleaven, J. (1995) Maintenance therapy for remission in myeloma with intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells Daytona, 13, 114-117.
24. Raje, N., Powels, R., Hickish, T., Milan, S., Horton, C., Mehta, J., Singhal, S., Treleaven, J. & Cunningham, D. (1995) Beta-2-microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance. Blood, 86, (Suppl. 1 ), 3351.
25. Salmon, S.E., Crowley, J.J., Grogan, T.M., Finley, P., Pugh, R.P. & Barlogie, B. (1994) Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 12, 2405-2414.
26. Tanaka, H., Tanabe, O., Iwato, K., Asaoku, H., Ishikawa, M., Nobuyoshi, M., Kawano, M. & Kuramoto, A. (1989) Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood, 74, 1718-1722.
27. The Nordic Myeloma Study Group (1996) Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Annals of Internal Medicine, 124, 212-222.
28. Tienhaara, A., Remes, K. & Pelliniemi, T.T. (1991) Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma. British Journal of Haematology, 77, 335-338.
29. Warburton, P., Dunn, J.A. & Maclennan, I.C.M. (1994) Cambridge Medical Reviews: Haematological Oncology, Vol. 3, pp. 95-114. Cambridge University Press.
30. Westin, J., Rodjer, S. & Turesson, I. (1995) Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. British Journal of Haematology, 89, 561-568.
31. Wisloff, F., Hjorth, M., Kaasa, S. & Westin, J. (1996) Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone + α-interferon. British Journal of Haematology, 94, 324-332.